Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2016-09-06
Source Title
Journal of Translational Medicine
Journal Title
Journal ISSN
Volume Title
Publisher
BIOMED CENTRAL LTD
Affiliation
Sir Peter MacCallum Department of Oncology
Microbiology and Immunology
Medicine (RMH)
Medicine (St Vincent's)
Microbiology and Immunology
Medicine (RMH)
Medicine (St Vincent's)
Document Type
Journal Article
Subject Code
Citation
Cooke, R. E., Gherardin, N. A., Harrison, S. J., Quach, H., Godfrey, D. I., Prince, M., Koldej, R. & Ritchie, D. S. (2016). Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma. Journal of Translational Medicine, 14 (1), pp.1-. https://doi.org/10.1186/s12967-016-0994-6.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
BACKGROUND: The Vk*MYC transgenic and transplant mouse models of multiple myeloma (MM) are well established as a research tool for anti-myeloma drug discovery. However, little is known of the immune response in these models. Understanding the immunological relevance of these models is of increasing importance as immunotherapeutic drugs are developed against MM. METHODS: We set out to examine how cellular immunity is affected in Vk*MYC mouse models and compare that to the immunology of patients with newly diagnosed and relapsed/refractory MM. RESULTS: We found that there were significant immunological responses in mice developing either spontaneous (transgenic) or transplanted MM as a consequence of the degree of tumor burden. Particularly striking were the profound B cell lymphopenia and the expansion of CD8(+) effector memory T cells within the lymphocyte population that progressively developed with advancing disease burden, mirroring changes seen in human MM. High disease burden was also associated with increased inflammatory cytokine production by T lymphocytes, which is more fitting with relapsed/refractory MM in humans. CONCLUSIONS: These findings have important implications for the application of this mouse model in the development of MM immunotherapies. Trial registration LitVacc ANZCTR trial ID ACTRN12613000344796; RevLite ANZCTR trial ID NCT00482261.